



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: August 13, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Subject: Newspaper Advertisement- Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above captioned subject, please find enclosed newspaper advertisement published in Financial Express and Loksatta on Saturday, August 13, 2022, containing extract of Unaudited Financial Results for the quarter ended June 30, 2022.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,
For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax: +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.- Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

**Aster DM Healthcare Limited**

CIN : L85110KA2008PLC147259

Registered office : No.1785, Sarjapur Road, Sector-1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India, Tel: +91 484 6699999 Email: cs@asterdmhealthcare.com Website: www.asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022
(Amount in INR crores except per share data)

Particulars	Consolidated				Standalone			
	For Quarter ended		For year ended		For Quarter ended		Year ended	
	30-Jun-22 (Unaudited)	31-Mar-22 (Audited)	30-Jun-21 (Unaudited)	31-Mar-22 (Audited)	30-Jun-22 (Unaudited)	31-Mar-22 (Audited)	30-Jun-21 (Unaudited)	31-Mar-22 (Audited)
Total income	2,699.39	2,749.77	2,379.63	10,303.94	336.76	345.33	259.52	1,198.67
Net profit/(loss) before tax	85.22	249.82	70.49	636.85	29.88	62.65	(7.42)	89.96
Net profit/(loss) after tax	79.77	245.63	59.60	601.05	29.88	62.87	(7.42)	90.18
Total comprehensive income/(loss)	158.00	317.90	79.04	694.50	29.88	63.33	(7.42)	90.64
Equity share capital	497.27	497.22	497.11	497.22	497.27	497.22	497.11	497.22
Other equity	-	-	-	3,456.19	-	-	-	2,457.99
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	1.38	4.55	0.89	10.58	0.60	1.26	(0.15)	1.81
Diluted	1.38	4.55	0.89	10.57	0.60	1.26	(0.15)	1.81

The unaudited consolidated and standalone financial results of the Company for the quarter ended June 30, 2022 have been reviewed by the Audit Committee of the Board on August 11, 2022 and approved by the Board of Directors at its meeting held on August 11, 2022.

The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial statements is made available on the Company's website at <https://www.asterdmhealthcare.com/investor/financial-information> and stock exchange website at BSE <https://www.bseindia.com/> and NSE <https://www.nseindia.com/>. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.For Aster DM Healthcare Limited
Sd/-Dr. Azad Moopen,
Chairman and Managing Director
DIN: 00159403Place : Kochi
Date : August 11, 2022**BADVE ENGINEERING LIMITED**

CIN: U73100MH1996PLC102827

Registered Office: Plot No. D-39, MIDC Area, Waluj, Aurangabad - 431133.

Website: www.badvegroup.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

(All amounts in ₹ Crore, except per share data)

Sr. No.	Particulars	Standalone			Consolidated		
		Quarter ended 30 th June, 2022	Quarter ended 31 st March, 2022	Year ended 31 st March, 2022	Quarter ended 30 th June, 2022	Quarter ended 31 st March, 2022	Year ended 31 st March, 2022
		(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)
1	Total income from operations	1,250.53	1,430.34	4,922.76	1,496.55	1,557.74	5,412.41
2	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	74.40	86.59	292.73	82.43	91.23	308.73
3	Net profit or loss for the period before tax (after Exceptional and/or Extraordinary items)	74.40	86.59	292.73	82.43	91.23	308.73
4	Net profit or loss for the period after tax (after Exceptional and/or Extraordinary items)	61.50	70.98	247.13	69.54	72.10	263.13
5	Total comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	59.63	64.31	268.41	67.66	65.43	284.42
6	Paid up Equity Share Capital	20.34	20.34	20.34	20.34	20.34	20.34
7	Reserves (excluding Revaluation Reserve)	1,681.71	1,622.09	1,622.09	1,723.39	1,653.83	1,653.83
8	Securities Premium Account	62.77	62.77	62.77	62.77	62.77	62.77
9	Net worth	1,702.05	1,642.43	1,642.43	1,743.73	1,674.17	1,674.17
10	Paid up Debt Capital/Outstanding Debt	2,548.89	2,597.96	2,597.96	2,703.78	2,597.96	2,597.96
11	Outstanding Redeemable Preference Shares	-	-	-	-	-	-
12	Debt Equity Ratio	1.50	1.58	1.58	1.55	1.55	1.55
13	Earnings Per Share (of ₹ 10/- each) For continuing or discontinued operations)						
	1. Basic:	30.00	35.00	121.00	34.00	35.00	129.00
	2. Diluted:	30.00	35.00	121.00	34.00	35.00	129.00
14	Capital Redemption Reserve	-	-	-	-	-	-
15	Debt Redemption Reserve	-	-	-	-	-	-
16	Debt Service Coverage Ratio	1.65	1.66	1.68	1.71	1.70	2.00
17	Interest Service Coverage Ratio	3.38	3.47	3.50	3.45	3.55	3.57
18	Current Ratio	1.34	1.37	1.37	1.43	1.38	1.38
19	Long Term Debt to Working Capital	2.62	2.71	2.71	2.14	2.54	2.54
20	Bad Debts to Accounts Receivable Ratio	-	-	-	-	-	-
21	Current Liability Ratio	0.50	0.47	0.47	0.50	0.48	0.48
22	Total Debt to Total Assets Ratio	0.49	0.51	0.51	0.49	0.50	0.50
23	Debtors Turnover Ratio	7.20	8.33	7.23	5.97	6.81	5.96
24	Inventory Turnover Ratio	11.52	12.95	11.16	12.69	13.04	11.42
25	Operating Margin [%]	17.5%	14.8%	15.9%	15.1%	13.8%	14.7%
26	Net Profit Margin [%]	5.1%	5.2%	5.2%	4.8%	4.8%	5.0%

- Notes:
- The above is an extract of the detailed format of unaudited quarterly financial results filed with the BSE Limited (stock exchange), under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). The full format of the unaudited quarterly financial results are available on the Company's website i.e. <http://www.badvegroup.com> and on the website of the Stock Exchange i.e. www.bseindia.com.
 - The aforesaid unaudited financial results of the Company were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th August 2022. The results for quarter ended June 30, 2022 have been reviewed by the Statutory Auditors of the Company and have provided their Limited Review Reports on the same.
 - For the other line items referred in the Regulation 52 (4) of the Listing Regulations, the pertinent disclosures have been made to the BSE Limited (stock exchange) and can be accessed on the URL <http://www.badvegroup.com> and <http://www.bseindia.com>.

For and on behalf of the Board of Directors

Sd/-
Shrikant Badve
Managing Director
DIN : 00295505Place : Pune
Date : 12th August 2022Credit Rating:
Brickworks Ratings India Private Limited has assigned/reaffirmed following credit rating to the Company

Aggregate amount of bank credit facilities rated	₹ 2,550.16 Crore
Long Term Fund Based credit facilities from Banks	BWR A+ /Stable Reaffirmed
Short Term Fund Based credit facilities from Banks	BWR A1 Reaffirmed
Short Term Non-Fund Based credit facilities from Banks	BWR A1 Reaffirmed
Aggregate amount of Non-Convertible Debentures:	₹ 300 Crore
NCDs issued of ₹ 235 Crore	BWR A+ /Stable Reaffirmed
Proposed NCDs of ₹ 65 Crore	Provisional BWR A+ /Stable Reaffirmed

The Credit Rating assigned by CRISIL Limited is "A/Stable".

Total Bank Loan Facilities Rated	₹ 2550 Crore (Enhanced from ₹ 2265 Crore)
Long Term Rating	CRISIL A/Stable (Reaffirmed)
Short Term Rating	CRISIL A1 (Reaffirmed)
Aggregate amount of Non-Convertible Debentures:	₹ 300 Crore
Rating on the ₹ 300 Crore Non Convertible Debentures	CRISIL A/Stable

Security Cover:
The Non-Convertible Debentures issued by the Company are secured by Movable and Immovable Properties as disclosed in the respective information memorandum dated 26th May 2020, 29th May 2020, 21st Aug 2021, and 17th Dec 2021 such that the aggregate value of the assets is equivalent to the minimum extent of 1.25 times of the outstanding secured obligations. The Company has created the charge on properties belonging to the Company situated in the State of Maharashtra, Gujarat, Karnataka and Rajasthan in favour of the Trustee for the benefit of the debenture holders. The Security Cover Certificate issued by the Statutory Auditor to this effect in terms of Regulation 54 of the Listing Regulations is submitted to Debenture Trustee.

Payment of Interest and Principal

There is no default in payment of interest and principal on NCDs. The Company has paid interest upto March 31, 2022 on outstanding NCDs, on March 29, 2022 itself. As on June 30, 2022, the details of principal amount, principal due date, previous interest payment due date, previous date of interest payment, next due date of interest payment and next interest payable are provided below:

₹ in Crore

ISIN No.	Debenture Series	Principal Amount	Principal Due Date	Previous Interest Payment due date	Previous date of Interest Payment	Next due date for Interest Payment	Next due amount of Interest Payable
INE894V07011	BEL-9.50%-28-5-23-PVT Tranche 1	60.00	28 th May, 2023	31 st March, 2022	29 th March, 2022	30 th Sept, 2022	2.86
INE894V07029	BEL-9.50%-2-6-23-PVT Tranche 2 Series A	50.00	2 nd June, 2023	31 st March, 2022	29 th March, 2022	30 th Sept, 2022	2.38
INE894V07037	BEL-9.50%-2-6-23-PVT Tranche 2 Series B	25.00	2 nd June, 2023	31 st March, 2022	29 th March, 2022	30 th Sept, 2022	1.19
INE894V07045	BEL-9.50%-29-8-24-PVT Tranche 3	50.00	29 th Aug, 2024	31 st March, 2022	29 th March, 2022	30 th Sept, 2022	2.37
INE894V07052	BEL-9.50%-23-12-24-PVT Tranche 4	50.00	23 rd Dec, 2024	-	-	23 rd Dec, 2022	4.75
Total		235.00					13.55

ARTEMIS HOSPITALS

OUR SPECIALITY IS YOU

ARTEMIS MEDICARE SERVICES LIMITED

Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Fax: +91-124-4588899; Email: investor@artemishospitals.com; Web site: www.artemishospitals.com

CIN: L85110DL2004PLC126414

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in Lacs)

S. No.	Particulars	Quarter Ended		Year Ended
		30 Jun 22	30 Jun 21	31 Mar 22
		(Unaudited)		(Audited)
1	Total Income from Operations	16,723.32	12,228.50	55,480.12
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	1,061.24	635.35	3,718.48
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	1,061.24	635.35	3,718.48
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	826.61	373.76	3,140.15
5	Total Comprehensive Income for the period [comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	818.24	388.90	3,106.68
6	Paid-up Equity Share Capital (Face value Re.1/-each)	1,328.27	1,323.77	1,323.77
7	Reserves (excluding Revaluation Reserve)	-	-	27,925.53
8	Earning per Equity Share (Face value Re.1/-each)			
	(a) Basic	0.64*	0.29*	2.40
	(b) Diluted	0.61*	0.28*	2.29
	(* Not annualised)			

Notes:

The key standalone financial information of the Company is as under:

(₹ in Lacs)

S. No.	Particulars	Quarter Ended		Year Ended
		30 Jun 22	30 Jun 21	31 Mar 22
		(Unaudited)		(Audited)
1	Total Income from Operations	16,346.59	12,048.27	54,478.40
2	Net Profit/(Loss) for the period before Tax after Exceptional Items	1,117.02	678.74	3,880.89
3	Net Profit/(Loss) for the period after Tax	869.81	415.71	3,257.74

The above is an extract of the detailed format of unaudited financial results filed with the Stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results (Consolidated/ Standalone) are available on the Stock Exchange websites. (National Stock Exchange of India Limited (www.nseindia.com) & BSE Limited (www.bseindia.com) and on the company's website (www.artemishospitals.com).

The above results for the quarter ended June 30, 2022 were reviewed by the Audit Committee meeting held on August 11, 2022 and approved by the Board of Directors meeting held on August 11, 2022. The Statutory Auditors have expressed an unmodified conclusion on the aforesaid results. The above financial results have been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

For and on behalf of the Board of Directors
of Artemis Medicare Services LimitedPlace : Gurugram
Dated : August 11, 2022Onkar Kanwar
Chairman**Sustainability.
Growth.
Profitability.****EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022**

(₹ In million, except per share data)

S. No.	Particulars	Quarter ended 30-06-2022	Quarter ended 31-03-2022	Quarter ended 30-06-2021	Year ended 31-03-2022
		Unaudited	Audited	Unaudited	Audited
		1	Total Revenue from Operations	1013.55	1812.69
2	Net Profit/(Loss) for the period (before Tax, Exceptional)	301.36	754.81	139.41	2072.45
3	Net Profit/(Loss) for the period before Tax, (after Exceptional)	301.36	754.81	139.41	2072.45
4	Net Profit/(Loss) for the period after Tax (after Exceptional)	252.49	462.11	77.39	1518.10
5	Total Comprehensive Income for the period (comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after tax)	(7.38)	1.17	0.04	(3.15)
6	Equity Share capital	160.97	160.97	146.37	160.97
7	Other Equity	6241.02	5942.63	2663.80	5942.63
8	Earning per share (of ₹ 2/- each) (not annualized)				
	1. Basic	3.14	5.74	0.96	18.86
	2. Diluted	3.14	5.74	0.96	18.86

Notes:

a) The Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of at its meeting held on August 12, 2022. The Auditors of the Company have carried out Limited Review of the Unaudited Financial Results for the Quarter Ended June 30, 2022.

b) The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites (www.bseindia.com), (www.nseindia.com) and Company's Website (www.supriyalifescience.com)

For Supriya Lifescience Limited

Sd/-

Saloni Wagh

Whole Time Director

DIN: 08491410

Place: Mumbai
Date: August 12, 2022**SUPRIYA LIFESCIENCE LIMITED**

CIN: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

